Loading...
XWAR
CLN
Market cap320mUSD
May 22, Last price  
22.40PLN
1D
-5.29%
1Q
-1.10%
IPO
-29.07%
Name

Celon Pharma SA

Chart & Performance

D1W1MN
P/E
—
P/S
7.34
EPS
—
Div Yield, %
0.36%
Shrs. gr., 5y
2.56%
Rev. gr., 5y
5.59%
Revenues
164m
+1.53%
40,109,16171,640,12598,099,063107,540,270128,777,939107,120,079125,244,805102,247,205139,270,000169,559,000161,915,000164,394,000
Net income
-28m
L-28.40%
1,333,50817,957,73252,207,12037,180,21537,807,41925,615,33229,697,10411,934,95821,495,000-11,607,000-39,277,000-28,124,000
CFO
-8m
L+76.86%
12,866,6868,450,09924,358,09952,368,29120,645,69925,302,74528,240,315070,904,00043,952,000-4,701,000-8,314,000
Dividend
Jun 27, 20240.08 PLN/sh
Earnings
Sep 16, 2025

Profile

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.
URL
https://celonpharma.com/
IPO date
Dec 01, 2016
Employees
521
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
164,394
1.53%
161,915
-4.51%
Cost of revenue
67,499
129,461
Unusual Expense (Income)
NOPBT
96,895
32,454
NOPBT Margin
58.94%
20.04%
Operating Taxes
8,156
2,831
Tax Rate
8.42%
8.72%
NOPAT
88,739
29,623
Net income
(28,124)
-28.40%
(39,277)
238.39%
Dividends
(4,595)
(14,800)
Dividend yield
0.58%
2.07%
Proceeds from repurchase of equity
2
4
BB yield
0.00%
0.00%
Debt
Debt current
19,880
19,434
Long-term debt
(4,337)
34,210
Deferred revenue
22,884
Other long-term liabilities
5,810
4,146
Net debt
(28,231)
(42,503)
Cash flow
Cash from operating activities
(8,314)
(4,701)
CAPEX
(32,813)
(33,906)
Cash from investing activities
(21,640)
(31,472)
Cash from financing activities
(20,589)
(28,721)
FCF
52,985
52,037
Balance
Cash
114,543
164,624
Long term investments
(70,769)
(68,477)
Excess cash
35,554
88,051
Stockholders' equity
(97,676)
479,646
Invested Capital
597,516
422,563
ROIC
17.40%
6.84%
ROCE
19.27%
6.34%
EV
Common stock shares outstanding
51,056
51,024
Price
15.46
10.27%
14.02
-57.71%
Market cap
789,333
10.34%
715,362
-53.77%
EV
761,102
672,859
EBITDA
146,911
76,549
EV/EBITDA
5.18
8.79
Interest
2,662
1,671
Interest/NOPBT
2.75%
5.15%